Totus Medicines closes $66M Series B to fund early-stage PI3Ka inhibitor, names new CEO

Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3Kα inhibitor through Phase Ia and has named Nassim Usman as its new president and CEO.

The Emeryville, CA-based Totus, which emerged with a $40 million Series A in December 2021, closed the Series B in recent weeks after Usman joined, he told Endpoints News. He replaces founding CEO Neil Dhawan, who will remain as chief scientific officer and add on head of R&D responsibilities, Totus said Friday morning.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Medicare may save $1.8B from four drugs in first year of price negotiations, research finds

A new paper published this week claims that in 2026, when Medicare negotiations for drug prices kick off, the minimum discount stipulated by the Inflation

August 3, 2023

High body temperature may boost gut microbiota to fight viral infections

Researchers from The University of Tokyo unravel the connection between high body temperature and increased viral resistance.

July 20, 2023

Cradle Bio raises $73M Series B to sell pharma its protein-making AI software

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.